{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:31:38Z","timestamp":1794569498594,"version":"4.9.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Contemporary survival data are not available for children with sickle cell disease (SCD). The few previous childhood SCD cohort studies do not reflect the benefits of modern therapy. We defined an inception cohort of newborns with sickle cell anemia (SS), sickle-\u03b2\u00b0-thalassemia (S \u03b2\u00b0), sickle-hemoglobin C disease (SC), or sickle-\u03b2+-thalassemia (S\u03b2+) who were identified by newborn screening and followed for up to 18 years. The incidence of death and stroke were calculated. Overall survival, SCD-related survival (considering only SCD-related deaths), and strokefree survival were determined. The 711 subjects provided 5648 patient-years of observation. Twenty-five subjects died; mean age at death was 5.6 years. Five patients died from infection. Thirty had at least one stroke. Among SS and S\u03b2\u00b0 subjects (n = 448), the overall rates of death and stroke were 0.59 and 0.85\/100 patient-years. Survival analysis of SS and S\u03b2\u00b0 subjects predicted the cumulative overall, SCD-related, and stroke-free survival to be 85.6%, 93.6%, and 88.5% by 18 years of age. No SCD-related deaths or strokes occurred in SC or S\u03b2+ subjects (n = 263). Childhood mortality from SCD is decreasing, the mean age at death is increasing, and a smaller proportion of deaths are from infection.<\/jats:p>","DOI":"10.1182\/blood-2003-11-3758","type":"journal-article","created":{"date-parts":[[2004,2,10]],"date-time":"2004-02-10T01:23:35Z","timestamp":1076376215000},"page":"4023-4027","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":294,"title":["Survival of children with sickle cell disease"],"prefix":"10.1182","volume":"103","author":[{"given":"Charles T.","family":"Quinn","sequence":"first","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, and Center for Cancer and Blood Disorders, Children's Medical Center Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora R.","family":"Rogers","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, and Center for Cancer and Blood Disorders, Children's Medical Center Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, and Center for Cancer and Blood Disorders, Children's Medical Center Dallas, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222182655600_REF1","doi-asserted-by":"crossref","unstructured":"Serjeant GR, Serjeant BE. Sickle Cell Disease 3rd ed. New York, NY: Oxford University Press; 2001.","DOI":"10.1046\/j.1365-2141.2001.02557.x"},{"key":"2020021222182655600_REF2","doi-asserted-by":"crossref","unstructured":"Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340: 1021-1030.","DOI":"10.1056\/NEJM199904013401307"},{"key":"2020021222182655600_REF3","doi-asserted-by":"crossref","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330: 1639-1644.","DOI":"10.1056\/NEJM199406093302303"},{"key":"2020021222182655600_REF4","doi-asserted-by":"crossref","unstructured":"Scott RB. Health care priority and sickle cell anemia. JAMA. 1970;214: 731-734.","DOI":"10.1001\/jama.1970.03180040039008"},{"key":"2020021222182655600_REF5","doi-asserted-by":"crossref","unstructured":"Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics. 1988;81: 749-755.","DOI":"10.1542\/peds.81.6.749"},{"key":"2020021222182655600_REF6","unstructured":"Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28: 220-226."},{"key":"2020021222182655600_REF7","doi-asserted-by":"crossref","unstructured":"Health supervision for children with sickle cell disease. Pediatrics. 2002;109: 526-535.","DOI":"10.1542\/peds.109.3.526"},{"key":"2020021222182655600_REF8","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332: 1317-1322.","DOI":"10.1056\/NEJM199505183322001"},{"key":"2020021222182655600_REF9","doi-asserted-by":"crossref","unstructured":"Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335: 369-376.","DOI":"10.1056\/NEJM199608083350601"},{"key":"2020021222182655600_REF10","doi-asserted-by":"crossref","unstructured":"Reed W, Vichinsky EP. Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease. J Pediatr Hematol Oncol. 2001;23: 197-202.","DOI":"10.1097\/00043426-200105000-00002"},{"key":"2020021222182655600_REF11","doi-asserted-by":"crossref","unstructured":"Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995;86: 776-783.","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776"},{"key":"2020021222182655600_REF12","doi-asserted-by":"crossref","unstructured":"Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;311: 1600-1602.","DOI":"10.1136\/bmj.311.7020.1600"},{"key":"2020021222182655600_REF13","doi-asserted-by":"crossref","unstructured":"Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258: 1205-1209.","DOI":"10.1001\/jama.1987.03400090089040"},{"key":"2020021222182655600_REF14","doi-asserted-by":"crossref","unstructured":"Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986; 314: 1593-1599.","DOI":"10.1056\/NEJM198606193142501"},{"key":"2020021222182655600_REF15","unstructured":"American Academy of Pediatrics: committee on Infectious Diseases. Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003."},{"key":"2020021222182655600_REF16","unstructured":"Therrell BL Jr, Brown LO, Dziuk PE, Peter WP Jr. The Texas Newborn Screening Program. Tex Med. 1983;79: 44-46."},{"key":"2020021222182655600_REF17","doi-asserted-by":"crossref","unstructured":"Therrell BL Jr, Simmank JL, Wilborn M. Experiences with sickle hemoglobin testing in the Texas Newborn Screening Program. Pediatrics. 1989; 83: 864-867.","DOI":"10.1542\/peds.83.5.864"},{"key":"2020021222182655600_REF18","unstructured":"Cox DR, Oakes D. Analysis of Survival Data. London, United Kingdom: Chapman and Hall; 1984."},{"key":"2020021222182655600_REF19","doi-asserted-by":"crossref","unstructured":"Bernini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr. 1995;126: 813-815.","DOI":"10.1016\/S0022-3476(95)70417-5"},{"key":"2020021222182655600_REF20","doi-asserted-by":"crossref","unstructured":"Assanasen C, Quinton RA, Buchanan GR. Acute myocardial infarction in sickle cell anemia. J Pediatr Hematol Oncol. 2003;25: 978-981.","DOI":"10.1097\/00043426-200312000-00015"},{"key":"2020021222182655600_REF21","unstructured":"Davis H, Gergen PJ, Moore RM. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep. 1997;112: 52-58."},{"key":"2020021222182655600_REF22","doi-asserted-by":"crossref","unstructured":"Davis H, Schoendorf KC, Gergen PJ, Moore RM. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87: 1317-1322.","DOI":"10.2105\/AJPH.87.8.1317"},{"key":"2020021222182655600_REF23","doi-asserted-by":"crossref","unstructured":"Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84: 500-508.","DOI":"10.1542\/peds.84.3.500"},{"key":"2020021222182655600_REF24","unstructured":"Powars DR. Natural history of sickle cell disease\u2014the first ten years. Semin Hematol. 1975; 12: 267-285."},{"key":"2020021222182655600_REF25","doi-asserted-by":"crossref","unstructured":"Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am J Hematol. 2002;70: 206-215.","DOI":"10.1002\/ajh.10140"},{"key":"2020021222182655600_REF26","doi-asserted-by":"crossref","unstructured":"Murthy VK, Haywood LJ. Survival analysis by sex, age group and hemotype in sickle cell disease. J Chronic Dis. 1981;34: 313-319.","DOI":"10.1016\/0021-9681(81)90069-2"},{"key":"2020021222182655600_REF27","doi-asserted-by":"crossref","unstructured":"Serjeant GR, Serjeant BE, Forbes M, Hayes RJ, Higgs DR, Lehmann H. Haemoglobin gene frequencies in the Jamaican population: a study in 100,000 newborns. Br J Haematol. 1986;64: 253-262.","DOI":"10.1111\/j.1365-2141.1986.tb04117.x"},{"key":"2020021222182655600_REF28","unstructured":"Powars D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Semin Hematol. 1990;27: 360-376."},{"key":"2020021222182655600_REF29","doi-asserted-by":"crossref","unstructured":"Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr. 1995;127: 685-690.","DOI":"10.1016\/S0022-3476(95)70154-0"},{"key":"2020021222182655600_REF30","doi-asserted-by":"crossref","unstructured":"Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. BMJ. 1982;285: 633-635.","DOI":"10.1136\/bmj.285.6342.633"},{"key":"2020021222182655600_REF31","unstructured":"Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91: 288-294."},{"key":"2020021222182655600_REF32","doi-asserted-by":"crossref","unstructured":"Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr. 1992;120: 360-366.","DOI":"10.1016\/S0022-3476(05)80897-2"},{"key":"2020021222182655600_REF33","doi-asserted-by":"crossref","unstructured":"Horan J, Lerner N. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342: 1612-1613.","DOI":"10.1056\/NEJM200005253422114"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/11\/4023\/1697775\/zh801104004023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/11\/4023\/1697775\/zh801104004023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T23:30:24Z","timestamp":1682638224000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/11\/4023\/17898\/Survival-of-children-with-sickle-cell-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-11-3758","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}